ACIBAN

Dosage : Tablet
Contains : Pantoprazole
Category : Proton pump inhibitor
Uses : Treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD)
Price :

Aciban is a trusted brand of Cadila Pharmaceuticals. It contains Pantoprazole, a proton pump inhibitor. It is used for the treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

 

Parietal (Stomach) cells secrete gastric acid through proton pumps. Aciban inhibits these proton pumps thereby reducing the secretion of acid in the stomach. Aciban is a prodrug and gets activated by acid present in stomach. Pantoprazole is the most acid stable drug of its class.

 

Aciloc RD is a product marketed by Cadila Pharmaceuticals. Cadila Pharmaceuticals Limited, established in 1951 is one of the largest privately held pharmaceuticals companies in India. It is an innovation and research focused company, which has been developing, manufacturing, selling and distributing pharmaceutical products across more than 45 therapeutic areas.

Your may have been prescribed Aciban because you could be suffering from Stomach Ulcers, Oesophageal Problems and other acidity related disorders.

 

Aciban is an orally available medication that contains the active substance Acibantoprazole. It works by reducing the amount of acid the stomach produces which helps heal any acid damage to the stomach and oesophagus.

 

Stomach ulcers are sores on the lining of the stomach and small intestine. This occurs when the protective mucus lining of the stomach becomes ineffective. If the mucus layer is worn away and stops functioning efficiently, the acid can damage the stomach tissue, causing an ulcer. Likewise, whenever the sphincter muscle at the lower end of the oesophagus relaxes at irregular time, allowing stomach acid to rush into the oesophagus which can cause heartburn and other signs.

 

Patients suffering from acidity related disorders like GERDs and stomach ulcers need to reduce the acid production in order to curb the damage to the stomach and oesophagus. Acibantoprazole can be used to treat acidity-related disorders and symptoms that may include:

 

  • Erosive Esophagitis
  • Gastroesophageal Reflux disease
  • Helicobacter pylori infection
  • Zollinger-Ellison syndrome
  • Gastro-duodenal ulcers
  • Oesophageal cancer
  • Heartburn
  • Difficulty in swallowing
  • Persistent cough

 

Aciban has been proven to work well among patients with stomach ulcer and oesophagus problems.

Dosage

As directed by your Physician

Administration

As directed by your Physician

Adverse Reactions/ Side Effects

Increased risk of Clostridium difficile-associated diarrhoea (CDAD). Headache, dizziness, nausea, vomiting, abdominal pain, flatulence, diarrhoea, constipation, dyspepsia, arthralgia, insomnia, rhinitis, inj site reaction (e.g. thrombophlebitis and abscess). Long-term treatment may lead to atrophic gastritis, symptomatic and asymptomatic hypomagnesaemia, cyanocobalamin malabsorption, and increased risk of osteoporosis-related fracture.

 

Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis and anaphylaxis.

Warnings and Precautions

Gastric malignancy should be ruled out. Consider Zn++ supplementation during IV therapy in patients who are prone to Zn++ deficiency. Pregnancy. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use.

Contraindications

Concomitant use w/ rilpivirine, atazanavir and nelfinavir. Lactation.

Drug Interactions

Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time of warfarin. May increase serum concentration of methotrexate and saquinavir. Delayed absorption and decreased bioavailability w/ sucralfate. Decreased absorption of ketoconazole, itraconazole.

Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine, atazanavir and nelfinavir.

Overdosage

–

Storage

Intravenous: Store between 20-25°C. Oral: Store between 20-25°C

Mechanism of Action

–

References

http://www.drugsupdate.com/generic/view/99

https://www.cadilapharma.com/about/overview/

If you are a healthcare practitioner and want additional material on the brand, disease, or molecule we have a few articles that can be hand-delivered by the company representative to you directly.

MEDIA

NEED FURTHER INFO?